Crestwood Advisors Group LLC Has $2.34 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Crestwood Advisors Group LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,799 shares of the pharmaceutical company’s stock after purchasing an additional 121 shares during the period. Crestwood Advisors Group LLC’s holdings in Vertex Pharmaceuticals were worth $2,335,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. NorthCrest Asset Manangement LLC increased its stake in Vertex Pharmaceuticals by 15.3% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 1,418 shares of the pharmaceutical company’s stock worth $660,000 after acquiring an additional 188 shares during the period. Arkadios Wealth Advisors acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $312,000. PFG Investments LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.8% during the 3rd quarter. PFG Investments LLC now owns 1,773 shares of the pharmaceutical company’s stock worth $825,000 after purchasing an additional 31 shares in the last quarter. GHP Investment Advisors Inc. increased its position in shares of Vertex Pharmaceuticals by 64.5% in the third quarter. GHP Investment Advisors Inc. now owns 102 shares of the pharmaceutical company’s stock worth $47,000 after purchasing an additional 40 shares during the period. Finally, Cavalier Investments LLC raised its stake in Vertex Pharmaceuticals by 6.0% in the third quarter. Cavalier Investments LLC now owns 7,297 shares of the pharmaceutical company’s stock valued at $3,394,000 after purchasing an additional 414 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on VRTX shares. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price objective on the stock. StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Truist Financial lifted their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a report on Friday, January 31st. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $481.65 on Tuesday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The stock has a market capitalization of $123.68 billion, a PE ratio of -218.93, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The stock’s 50 day simple moving average is $436.32 and its 200 day simple moving average is $460.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.